Neumora Therapeutics
NMRA
93 hedge funds and large institutions have $627M invested in Neumora Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 13 reducing their positions, and 19 closing their positions.
223% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 13
127% more call options, than puts
Call options by funds: $1.81M | Put options by funds: $797K
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6.85% more ownership
Funds ownership: 33.17% → 40.01% (+6.8%)
6% more funds holding
Funds holding: 88 → 93 (+5)
14% less capital invested
Capital invested by funds: $725M → $627M (-$98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$37.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.4M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$15.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.8M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$10.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.97M |
| 3 |
SCM
Soros Capital Management
New York
|
-$4.09M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
-$3.43M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.19M |
NMRA Hedge Fund Activity: Q2 2024 in Review
93 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2024, worth a combined $627M — down 14% from $725M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NMRA positions and 19 closed out — a net gain of 5 holders — while 42 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $37.4M. The largest seller was Deep Track Capital, exiting entirely with an estimated $10.3M sold.
- 93 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2024, up from 88 in Q1 2024.
- Funds reported $627M of Neumora Therapeutics stock for Q2 2024, down 14% quarter-over-quarter.
- 24 funds opened new Neumora Therapeutics positions in Q2 2024 and 19 closed out, a net change of +5 holders.
- The largest Neumora Therapeutics buyer in Q2 2024 was BlackRock, an estimated $37.4M added.
- The largest Neumora Therapeutics seller in Q2 2024 was Deep Track Capital, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2024.